Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives
Open accessThe DOI matches its Crossref record; 121 of the 123 references it cites were found in a registry or an index.
Abstract
The vasculature is a key player and regulatory component in the multicellular microenvironment of solid tumors and, consequently, a therapeutic target. In colorectal carcinoma (CRC), antiangiogenic treatment was approved almost 20 years ago, but there are still no valid predictors of response. In addition, treatment resistance has become a problem. Vascular heterogeneity and plasticity due to species-, organ-, and milieu-dependent phenotypic and functional differences of blood vascular cells reduced the hope of being able to apply a standard approach of antiangiogenic therapy to all patients. In addition, the pathological vasculature in CRC is characterized by heterogeneous perfusion, impaired barrier function, immunosuppressive endothelial cell anergy, and metabolic competition-induced microenvironmental stress. Only recently, angiocrine proteins have been identified that are specifically released from vascular cells and can regulate tumor initiation and progression in an autocrine and paracrine manner. In this review, we summarize the history and current strategies for applying antiangiogenic treatment and discuss the associated challenges and opportunities, including normalizing the tumor vasculature, modulating milieu-dependent vascular heterogeneity, and targeting functions of angiocrine proteins. These new strategies could open perspectives for future vascular-targeted and patient-tailored therapy selection in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Different types of vessels are present in human colorectal cancer tissues. In human CRC, blood vessels can be labeled using the markers CD31 or vWF. Lymphatic vessels may be stained with LYVE-1 or podoplanin. Arteries and veins can be differentiated by labeling using the artery marker ephrinB2. This may be complemented by morphological differentiation of arteries (A) and veins (V) together with analysis of milieu-dependent expression of vessel markers such as SPARCL1. CD31, vWF, LYVE-1 and podoplanin panels: 25x objective; ephrinB2 and SPARCL1 panels: scale bars corresponding to 50 µm. The vWF panel is modified from Schellerer et al., Lab Invest 2007 [97].](https://figures.cochat.ai/paper-figures/1940b3d38be94f6e8167c8cad8a8a2b7/blood-vessel-targeted-therapy-in-colorectal-cancer-current-strategies-and-future-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“since anti-angiogenic therapies lead to only modest increases in survival for CRC patients”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [211]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Anti-angiogenic therapies, which inhibit the growth of new blood vessels, are currently given in combination with chemotherapy to treat patients with advanced or metastatic CRC [211].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…15 years ago, it became clear that not only tumor cells alone but also the interplay of tumor cells with the different cell types in the surrounding stroma mediated by many different cytokines and growth factors is a paramount denominator of tumor progression and therapeutic responses [5].”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 4×
“Unfortunately, as detailed in the previous section, antiangiogenic treatment combined with chemotherapy causes only mild increases in survival, low response rates and moderate efficacy [19].”
BackgroundInfluentialTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“His hypothesis was that vessels are needed for the delivery of nutrients to tumor cells and that blocking vessel growth into tumors may consequently reduce tumor progression [6].”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Disease-and patient-dependent heterogeneity of tumor endothelial cells has clearly been demonstrated by multiregion sequencing of renal carcinoma [92], and this approach may similarly apply to CRC.”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“This results in the restoration of vascular maturation, increased capacity to sustain tissue pressure and normalization of the basement membrane [75].”
BackgroundEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 2×
“These inhibitors were named angiostatin, a cleavage product of the blood protein plasminogen involved in fibrolyis, and endostatin, a cleavage product of the extracellular matrix protein collagen XVIII [13,14].”
BackgroundO'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345 · cited 2×
“These inhibitors were named angiostatin, a cleavage product of the blood protein plasminogen involved in fibrolyis, and endostatin, a cleavage product of the extracellular matrix protein collagen XVIII [13,14].”
BackgroundSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · cited 1×
“Sidedness was also addressed in a retrospective subgroup analysis of the two pivotal first-line bevacizumab trials of Hurwitz et al. (2004) [19] and Saltz et al. (2008) [37] mentioned above.”
BackgroundGrothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 2×
“Regorafenib had a statistically significant, but only moderate, effect on OS (6.4 vs. 5.0 months) as monotherapy for chemorefractory patients with mCRC compared to placebo in the phase III multicenter CORRECT trial [25].”
BackgroundInfluentialVEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302047 · Cited by 2,894
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Global Burden of 5 Major Types of Gastrointestinal Cancer
Arnold, M., Abnet, C. C., Neale, R. E., Vignat, J., Giovannucci, E. L., McGlynn, K. A., & Bray, F. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.068 · Cited by 2,027 · cited 4×
“CRC incidence rates remain high in highly developed countries such as Canada and Northern Europe and are rising rapidly in many less developed countries, particularly in Eastern Europe, Asia and South America [2].”
BackgroundInfluentialHashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922 · cited 2×
“…FOLFOX, FOLFIRI or the triplet FOLFOXIRI is recommended for right-sided RAS-and BRAF-wt mCRC but also for RAS-mut and BRAF-mut mCRC, independent of the sidedness [4,28], although its efficacy, in particular in combination with potent chemotherapies as FOLFOX, FOLFIRI or FOLFOXIRI is still unclear.”
BackgroundCervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796 · cited 3×
“…FOLFOX, FOLFIRI or the triplet FOLFOXIRI is recommended for right-sided RAS-and BRAF-wt mCRC but also for RAS-mut and BRAF-mut mCRC, independent of the sidedness [4,28], although its efficacy, in particular in combination with potent chemotherapies as FOLFOX, FOLFIRI or FOLFOXIRI is still unclear.”
BackgroundHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · cited 1×
“…FOLFIRI/bevacizumab as first-line treatment for patients with KRAS wild-type (wt) mCRC in a randomized phase III trial (FIRE-3) and reported a significantly prolonged OS in the cetuximab group (28.7 vs. 25.0 months in the bevacizumab group), although RR and PFS did not significantly differ [40].”
MethodInfluentialKabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716 · cited 1×
“Kabbinavar et al. [34] reported a dose-dependent positive effect of bevacizumab in combination with 5-FU/leucovorin on the RR, PFS and OS in a phase II trial in patients with mCRC. Hurwitz et al. [19] also reported better outcomes for all three parameters for patients treated with bevacizumab in…”
BackgroundColon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696 · cited 1×
“However, only bevacizumab is recommended in first-line setting [4,28,29].”
BackgroundAntiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402 · cited 2×
“In a phase III clinical trial, patients treated with aflibercept in combination with FOLFIRI had significantly better OS (13.5 vs. 12.6 months) and PFS (6.9 vs. 4.7 months) than did patients treated with FOLFIRI/placebo in second-line therapy after previous treatment with oxaliplatin [23].”
BackgroundResultInfluentialTumour vascularization via endothelial differentiation of glioblastoma stem-like cells
Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M., et al. (2010) · Nature · doi:10.1038/nature09557 · Cited by 1,379
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,299 · cited 2×
“Fumagillin was shown to be an antiangiogenic agent when Folkman’s coworker revealed that it inhibited capillary endothelial cell proliferation in Aspergillus fumigatus -contaminated cell cultures [12].”
BackgroundGlioblastoma stem-like cells give rise to tumour endothelium
Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C., & Tabar, V. (2010) · Nature · doi:10.1038/nature09624 · Cited by 1,203 · cited 1×
“This was highlighted for GBM patients, in which endothelial cell-like cells were found to transdifferentiate from GBM stem-like cells [112–114].”
BackgroundAngiostatin induces and sustains dormancy of human primary tumors in mice
O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,184 · cited 1×
“Moreover, endostatin and angiostatin strongly inhibited the growth of many different tumors, including breast, colorectal and lung cancer, in different mouse models [15].”
BackgroundKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170 · cited 1×
“This concept is supported by the observation that cytotoxic therapy results in a better outcome within the window of tumor vessel normalization than did cytotoxic therapy before or after [76].”
BackgroundBennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159 · cited 2×
“Bevacizumab, the first approved antiangiogenic drug, binds to VEGF-A and prevents its binding to the corresponding receptors [27].”
BackgroundThe perivascular niche regulates breast tumour dormancy
Ghajar, C. M., Peinado, H., Mori, H., Matei, I. R., Evason, K. J., Brazier, H., Almeida, D., Koller, A., Hajjar, K. A., Stainier, D. Y. R., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2767 · Cited by 1,148 · cited 1×
“Thrombo-spondin-1 is an angiocrine molecule with antitumorigenic functions that has been shown to induce tumor dormancy in the perivascular niche in breast cancer [101].”
BackgroundTumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035 · cited 1×
“Immune tolerance can be pharmacologically attenuated by VEGF and PGE 2 inhibition [108].”
BackgroundTabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952 · cited 2×
“Ramucirumab is a human immunoglobulin G1 (IgG 1) monoclonal antibody that blocks VEGF receptor 2 (VEGFR-2), thereby preventing its activation [24].”
BackgroundInfluentialKabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898 · cited 1×
“Venook et al. conducted a similar trial (CALGB/SWOG 80405) to test either FOLFIRI or FOLFOX plus cetuximab or bevacizumab and found no differences in OS, PFS and RR between bevacizumab and cetuximab [41].”
Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70154-2 · Cited by 643 · cited 1×
“Although some of the studies reported improved PFS, the OS did not improve by adding bevacizumab [21,35–38].”
BackgroundSchwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.-L., Hecht, J. R., Yu, H., Oliner, K. S., & Go, W. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2473 · Cited by 635
Is early-onset cancer an emerging global epidemic? Current evidence and future implications
Ugai, T., Sasamoto, N., Lee, H.-Y., Ando, M., Song, M., Tamimi, R. M., Kawachi, I., Campbell, P. T., Giovannucci, E. L., Weiderpass, E., et al. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00672-8 · Cited by 603 · cited 1×
“Since the 1990s, despite an overall downward trend, particularly in high-income countries, there has been an increase in digestive tract cancers in adults under the age of 50 [3].”
BackgroundNolan, D. J., Ginsberg, M., Israely, E., Palikuqi, B., Poulos, M. G., James, D., Ding, B.-S., Schachterle, W., Liu, Y., Rosenwaks, Z., et al. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.06.017 · Cited by 603 · cited 1×
“The abovementioned examples of EC heterogeneity, organ-dependent heterogeneity and the function of TECs are considered causes of differential responses to antiangiogenic treatment [93,94].”
BackgroundSchmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582 · cited 1×
“Notably, efforts are also underway to optimize the combination schedules of different drugs by developing algorithms that predict optimal low-dose drug combinations to improve the outcome of antiangiogenic treatment, and these algorithms have shown beneficial effects [85,88].”
BackgroundAdverse effects of anticancer agents that target the VEGF pathway
Chen, H. X., & Cleck, J. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.94 · Cited by 560 · cited 1×
“Toxicity and adverse effects, including hypertension, proteinuria, hemorrhage, GI perforation, wound complications, and thromboembolic events, are mostly modest and manageable [30–33].”
BackgroundHolch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534 · cited 1×
“The authors concluded that patients with left-sided RAS-wt mCRC benefit from treatment with an anti-EGFR antibody, whereas bevacizumab should be preferred for right-sided mCRC [43].”
BackgroundVan Cutsem, E., Rivera, F., Berry, S., Kretzschmar, A., Michael, M., DiBartolomeo, M., Mazier, M.-A., Canon, J.-L., Georgoulias, V., Peeters, M., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp233 · Cited by 532
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530 · cited 2×
“In the context of tumor vessel normalization, also defined as vessel pruning and regression, oxygenation and perfusion of the tumor improve in association with a reduction in tumor vessel size and tortuosity [74].”
BackgroundTrifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer
Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214963 · Cited by 467 · cited 1×
“…therapy in combination with trifluridine-tipiracil, as the SUNLIGHT trial showed a relevant improvement in OS (10.8 versus 7.5 months) and PFS (5.6 versus 2.4 months) for patients treated with trifluridine-tipiracil plus bevacizumab compared to those treated with trifluridine-tipiracil alone [47].”
ResultInfluentialVessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A., Gao, Z.-H., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 454 · cited 1×
“In conclusion, both TEC heterogeneity and the different mechanisms through which tumor cells arrange their supply of oxygen and nutrients cause the tumor vasculature to be a more complex target, as initially appreciated [77,78,96].”
BackgroundJackstadt, R., van Hooff, S. R., Leach, J. D., Cortes-Lavaud, X., Lohuis, J. O., Ridgway, R. A., Wouters, V. M., Roper, J., Kendall, T. J., Roxburgh, C. S., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.003 · Cited by 433 · cited 1×
“Meanwhile, novel organoid-based in vivo animal models that recapitulate spontaneous distant metastasis similar to that observed in human patients have been established; therefore, these models have great potential for improving preclinical screening [121,122].”
BackgroundLi, J., Qin, S., Xu, R.-H., Shen, L., Xu, J., Bai, Y., Yang, L., Deng, Y., Chen, Z.-D., Zhong, H., et al. (2018) · JAMA · doi:10.1001/jama.2018.7855 · Cited by 425 · cited 2×
“The authors state that the results may not be applicable to the Western population, as the standard treatment for mCRC in China does not include anti-VEGF therapy in prior therapy lines [53].”
BackgroundInfluentialTebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7723 · Cited by 413 · cited 1×
“Although some of the studies reported improved PFS, the OS did not improve by adding bevacizumab [21,35–38].”
BackgroundShigeta, K., Datta, M., Hato, T., Kitahara, S., Chen, I. X., Matsui, A., Kikuchi, H., Mamessier, E., Aoki, S., Ramjiawan, R. R., et al. (2020) · Hepatology · doi:10.1002/hep.30889 · Cited by 409 · cited 1×
“Accordingly, the combination of antiangiogenic treatment with immunomodulatory drugs has great additional potential by overcoming milieu-dependent immunosuppressive functions and further increasing therapeutic efficacy by fostering vessel normalization [86,87].”
BackgroundDasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00772-9 · Cited by 368 · cited 2×
“The results showed a promising effect of fruquintinib in the treatment of patients with advanced, chemotherapy-refractory mCRC, with an OS of 7.4 months in the fruquintinib group versus 4.8 months in the placebo group [26].”
BackgroundInfluentialDirkx, A. E. M., Egbrink, M. G. A. O., Kuijpers, M. J. E., van der Niet, S. T., Heijnen, V. V. T., Steege, J. C. A. B.-T., Wagstaff, J., & Griffioen, A. W. (2003) · PubMed · Cited by 325
Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas
Streubel, B., Chott, A., Huber, D., Exner, M., Jäger, U., Wagner, O., & Schwarzinger, I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033153 · Cited by 318 · cited 1×
“For example, in B-cell lymphoma patients, tumor cell-specific genetic alterations have been detected in microvascular endothelial cells [109].”
BackgroundTargeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315 · cited 4×
“Due to this low selectivity, TKIs often cause serious toxicity, making their clinical use challenging, particularly in combination with chemotherapy [51].”
BackgroundMethodInfluentialVascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α
Wang, Q., He, Z., Huang, M., Liu, T., Wang, Y., Xu, H., Duan, H., Ma, P., Zhang, L., Zamvil, S. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03050-0 · Cited by 277 · cited 2×
“…were described for vascular-derived IL-6 in glioblastoma (GBM), which induces TME-dependent alternative macrophage polarization by activating HIF-2 α and arginase-1, resulting in GBM progression [99], or for TEC-derived jagged-1, which induces B-cell lymphoma invasiveness and chemoresistance [79].”
BackgroundCross-talk between calcium and reactive oxygen species signaling
YAN, Y., WEI, C.-L., ZHANG, W.-R., CHENG, H.-P., & LIU, J. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00390.x · Cited by 259 · cited 1×
“ROS and calcium are two closely interconnected signaling molecules in eukaryotic cells, and calcium is known to modulate ROS homeostasis [117].”
BackgroundHegewisch-Becker, S., Graeven, U., Lerchenmüller, C. A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00042-x · Cited by 251
Cao, Z., Ding, B.-S., Guo, P., Lee, S. B., Butler, J. M., Casey, S. C., Simons, M., Tam, W., Felsher, D. W., Shido, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.005 · Cited by 223 · cited 2×
“…were described for vascular-derived IL-6 in glioblastoma (GBM), which induces TME-dependent alternative macrophage polarization by activating HIF-2 α and arginase-1, resulting in GBM progression [99], or for TEC-derived jagged-1, which induces B-cell lymphoma invasiveness and chemoresistance [79].”
Backgroundvan der Schaft, D. W. J., Seftor, R. E. B., Seftor, E. A., Hess, A. R., Gruman, L. M., Kirschmann, D. A., Yokoyama, Y., Griffioen, A. W., & Hendrix, M. J. C. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh267 · Cited by 219 · cited 1×
“Both types of tumor vasculature formation have implications for therapy by fostering resistance, as observed for vessels assembled by melanoma and endothelial cells [111].”
BackgroundMyelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
Kumar, R., Crouthamel, M.-C., Rominger, D. H., Gontarek, R. R., Tummino, P. J., Levin, R. A., & King, A. G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605366 · Cited by 218 · cited 1×
“Antiangiogenic tyrosine kinase inhibitors (TKIs) are small molecules that traditionally affect a wide range of tyrosine and serine-threonine kinases in addition to the intended VEGFR signaling pathway [50].”
BackgroundBridgeman, V. L., Vermeulen, P. B., Foo, S., Bilecz, A., Daley, F., Kostaras, E., Nathan, M. R., Wan, E., Frentzas, S., Schweiger, T., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4845 · Cited by 214 · cited 1×
“In conclusion, both TEC heterogeneity and the different mechanisms through which tumor cells arrange their supply of oxygen and nutrients cause the tumor vasculature to be a more complex target, as initially appreciated [77,78,96].”
BackgroundSchmoll, H.-J., Cunningham, D., Sobrero, A., Karapetis, C. S., Rougier, P., Koski, S. L., Kocakova, I., Bondarenko, I., Bodoky, G., Mainwaring, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5355 · Cited by 213
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
van Beijnum, J. R., Nowak-Sliwinska, P., Huijbers, E. J. M., Thijssen, V. L., & Griffioen, A. W. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010215 · Cited by 211 · cited 1×
“Finally, tumor vessel invasion may arise through different mechanisms, such as vessel co-option or vascular mimicry, which are not necessarily dependent on active angiogenesis and, accordingly, may result in resistance to antiangiogenic treatment approaches [95].”
BackgroundZhao, Q., Eichten, A., Parveen, A., Adler, C., Huang, Y., Wang, W., Ding, Y., Adler, A., Nevins, T., Ni, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2728 · Cited by 205 · cited 1×
“The abovementioned examples of EC heterogeneity, organ-dependent heterogeneity and the function of TECs are considered causes of differential responses to antiangiogenic treatment [93,94].”
BackgroundCytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors
Akino, T., Hida, K., Hida, Y., Tsuchiya, K., Freedman, D., Muraki, C., Ohga, N., Matsuda, K., Akiyama, K., Harabayashi, T., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090202 · Cited by 183 · cited 1×
“Furthermore, increased aneuploidy was detected in TECs in human renal carcinoma [115] and in mouse melanoma models with high and low metastatic potential [116].”
BackgroundHecht, J. R., Trarbach, T., Hainsworth, J. D., Major, P., Jäger, E., Wolff, R. A., Lloyd-Salvant, K., Bodoky, G., Pendergrass, K., Berg, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.4496 · Cited by 178
Passardi, A., Nanni, O., Tassinari, D., Turci, D., Cavanna, L., Fontana, A., Ruscelli, S., Mucciarini, C., Lorusso, V., Ragazzini, A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv130 · Cited by 177 · cited 1×
“Although some of the studies reported improved PFS, the OS did not improve by adding bevacizumab [21,35–38].”
BackgroundGalectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance
Nambiar, D. K., Aguilera, T., Cao, H., Kwok, S., Kong, C., Bloomstein, J., Wang, Z., Rangan, V. S., Jiang, D., von Eyben, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129025 · Cited by 176 · cited 1×
“An immunosuppressive function of the endothelial barrier has been reported for galectin-1-driven T-cell exclusion in the tumor endothelium, promoting immunotherapy resistance [107].”
BackgroundMasi, G., Salvatore, L., Boni, L., Loupakis, F., Cremolini, C., Fornaro, L., Schirripa, M., Cupini, S., Barbara, C., Safina, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv012 · Cited by 172 · cited 1×
“In second-line treatment, the combination of chemotherapy and bevacizumab compared to chemotherapy alone improved OS and PFS in different phase III trials, although the absolute benefit was only 1–2 months in terms of the median OS [46].”
BackgroundHelfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091846 · Cited by 170 · cited 3×
“In conclusion, both TEC heterogeneity and the different mechanisms through which tumor cells arrange their supply of oxygen and nutrients cause the tumor vasculature to be a more complex target, as initially appreciated [77,78,96].”
BackgroundHeterogeneity of Tumor Endothelial Cells
Ohga, N., Ishikawa, S., Maishi, N., Akiyama, K., Hida, Y., Kawamoto, T., Sadamoto, Y., Osawa, T., Yamamoto, K., Kondoh, M., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.11.035 · Cited by 166 · cited 1×
“Furthermore, increased aneuploidy was detected in TECs in human renal carcinoma [115] and in mouse melanoma models with high and low metastatic potential [116].”
BackgroundVan Cutsem, E., Bajetta, E., Valle, J., Köhne, C.-H., Randolph Hecht, J., Moore, M., Germond, C., Berg, W., Chen, B.-L., Jalava, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5436 · Cited by 163
Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.200918462104c · Cited by 163
Judah Folkman, a pioneer in the study of angiogenesis
Ribatti, D. (2008) · Angiogenesis · doi:10.1007/s10456-008-9092-6 · Cited by 157 · cited 4×
“Moreover, in recent years , it has become clear that ECs in tumors are not just passive conduits of blood that deliver oxygen, nutrients and circulating cells or remove waste products from tissues. is modified from Schellerer et al., Lab Invest 2007 [97].”
BackgroundInfluentialHuang, X., Bai, X., Cao, Y., Wu, J., Huang, M., Tang, D., Tao, S., Zhu, T., Liu, Y., Yang, Y., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090397 · Cited by 156 · cited 1×
“Moreover, compensatory functions of the lymphatic vessel system must be considered [91].”
BackgroundHoff, P. M., Hochhaus, A., Pestalozzi, B. C., Tebbutt, N. C., Li, J., Kim, T. W., Koynov, K. D., Kurteva, G., Pintér, T., Cheng, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6031 · Cited by 155
Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Li, Q., Wang, Y., Jia, W., Deng, H., Li, G., Deng, W., Chen, J., Kim, B. Y. S., Jiang, W., Liu, Q., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2179 · Cited by 152 · cited 2×
“Additionally, the combination of angiopoietin-2 (ANG2) blockade and VEGF plus immunotherapy is currently being investigated and has shown promising results [82,84–86].”
BackgroundVascular Microenvironment, Tumor Immunity and Immunotherapy
Lamplugh, Z. L., & Fan, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.811485 · Cited by 140 · cited 1×
“Additionally, the combination of angiopoietin-2 (ANG2) blockade and VEGF plus immunotherapy is currently being investigated and has shown promising results [82,84–86].”
BackgroundAnti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues
Yang, Y., Zhang, Y., Cao, Z., Ji, H., Yang, X., Iwamoto, H., Wahlberg, E., Länne, T., Sun, B., & Cao, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301331110 · Cited by 139 · cited 1×
“As an example of the therapeutic consequences of EC heterogeneity, it can be noted that the normal vasculature regresses along with the tumor vasculature upon treatment, indicating that not even TECs as a whole can be specifically targeted, not considering that different TEC populations exist [90].”
BackgroundAN ANTIPHAGE AGENT ISOLATED FROM ASPERGILLUS SP
Hanson, F. R., & Eble, T. E. (1949) · Journal of Bacteriology · doi:10.1128/jb.58.4.527-529.1949 · Cited by 129 · cited 1×
“Among these substances was fumagillin, which was first isolated from Aspergillus fumigatus in 1949 as an antiphage agent [10,11].”
BackgroundFruquintinib: First Global Approval
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0998-z · Cited by 128
Mettu, N. B., Ou, F.-S., Zemla, T. J., Halfdanarson, T. R., Lenz, H.-J., Breakstone, R. A., Boland, P. M., Crysler, O. V., Wu, C., Nixon, A. B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.49040 · Cited by 126 · cited 1×
“The most common treatment regimens are anti-VEGF therapy in combination with PD-1 blockade, for example, the addition of atezolizumab (an anti-PD-L1 antibody) to capecitabine and bevacizumab [83].”
BackgroundSiu, L. L., Shapiro, J. D., Jonker, D. J., Karapetis, C. S., Zalcberg, J. R., Simes, J., Couture, F., Moore, M. J., Price, T. J., Siddiqui, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.0543 · Cited by 126
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
Weiss, A., Ding, X., B, J. R. V. B., Wong, I., Wong, T. J., Berndsen, R. H., Dormond, O., Dallinga, M. G., Shen, L., Schlingemann, R. O., et al. (2015) · Angiogenesis · doi:10.1007/s10456-015-9462-9 · Cited by 124 · cited 1×
“Notably, efforts are also underway to optimize the combination schedules of different drugs by developing algorithms that predict optimal low-dose drug combinations to improve the outcome of antiangiogenic treatment, and these algorithms have shown beneficial effects [85,88].”
BackgroundZheng, Y., Zhou, R., Cai, J., Yang, N., Wen, Z., Zhang, Z., Sun, H., Huang, G., Guan, Y., Huang, N., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0025 · Cited by 105 · cited 1×
“…patients, increased matrix stiffness was detected, which resulted in lipid metabolic cross-talk between the tumor and stromal cells characterized by increased levels of ROS and free fatty acids and a higher fatty acid oxidation rate, all of which contributed to bevacizumab resistance [118].”
BackgroundGuruceaga, X., Perez-Cuesta, U., Abad-Diaz de Cerio, A., Gonzalez, O., Alonso, R. M., Hernando, F. L., Ramirez-Garcia, A., & Rementeria, A. (2019) · Toxins · doi:10.3390/toxins12010007 · Cited by 104 · cited 1×
“Among these substances was fumagillin, which was first isolated from Aspergillus fumigatus in 1949 as an antiphage agent [10,11].”
BackgroundDi Tacchio, M., Macas, J., Weissenberger, J., Sommer, K., Bähr, O., Steinbach, J. P., Senft, C., Seifert, V., Glas, M., Herrlinger, U., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0865 · Cited by 104 · cited 3×
“Accordingly, the combination of antiangiogenic treatment with immunomodulatory drugs has great additional potential by overcoming milieu-dependent immunosuppressive functions and further increasing therapeutic efficacy by fostering vessel normalization [86,87].”
BackgroundAKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer
Varga, J., Nicolas, A., Petrocelli, V., Pesic, M., Mahmoud, A., Michels, B. E., Etlioglu, E., Yepes, D., Häupl, B., Ziegler, P. K., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191515 · Cited by 93 · cited 1×
“Meanwhile, novel organoid-based in vivo animal models that recapitulate spontaneous distant metastasis similar to that observed in human patients have been established; therefore, these models have great potential for improving preclinical screening [121,122].”
BackgroundNaschberger, E., Liebl, A., Schellerer, V. S., Schütz, M., Britzen‐Laurent, N., Kölbel, P., Schaal, U., Haep, L., Regensburger, D., Wittmann, T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci78260 · Cited by 93 · cited 1×
“Specifically, the antitumorigenic functions of angiocrine tumor vessel activities may have an unappreciated clinical impact on the outcome of antiangiogenic therapy [100].”
BackgroundSelf-citationZhang, Y., Zou, J.-Y., Wang, Z., & Wang, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s215533 · Cited by 82 · cited 2×
“It is a small molecule that is orally applied and, in contrast to regorafenib, exhibits high selectivity for VEGFR-1, -2 and -3 [52].”
BackgroundPeeters, M., Strickland, A. H., Lichinitser, M., Suresh, A. V. S., Manikhas, G., Shapiro, J., Rogowski, W., Huang, X., Wu, B., Warner, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.594 · Cited by 79
Novel anti-angiogenic therapeutic strategies in colorectal cancer
Tampellini, M., Sonetto, C., & Scagliotti, G. V. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1161754 · Cited by 77 · cited 2×
“Toxicity and adverse effects, including hypertension, proteinuria, hemorrhage, GI perforation, wound complications, and thromboembolic events, are mostly modest and manageable [30–33].”
BackgroundBaraniskin, A., Buchberger, B., Pox, C., Graeven, U., Holch, J. W., Schmiegel, W., & Heinemann, V. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.009 · Cited by 73 · cited 1×
“Bevacizumab in first-line therapy seems to improve both OS and PFS when combined with fluoropyrimidine monotherapy, for example for patients with reduced general health, but only PFS when combined with commonly recommended combined chemotherapies based on infusional 5-FU (FOLFOX, FOLFIRI) [39].”
BackgroundKerbel, R. S., & Shaked, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.005 · Cited by 69 · cited 1×
“The application of such metronomic schedules showed an increased clinical benefit, particularly in the metastatic disease setting, together with the advantage of lower overall toxicity [80].”
BackgroundVan Cutsem, E., Yoshino, T., Lenz, H. J., Lonardi, S., Falcone, A., Limón, M. L., Saunders, M., Sobrero, A., Park, Y. S., Ferreiro, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy241 · Cited by 63
A review of Judah Folkman's remarkable achievements in biomedicine
Cao, Y., & Langer, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806582105 · Cited by 62 · cited 2×
“It was shown that TECs in CRC are epigenetically imprinted in a TME - dependent manner , resulting in stably maintained differential phenotypes with an impact on patient prognosis [9 8 ] .”
BackgroundSouglakos, J., Ziras, N., Kakolyris, S., Boukovinas, I., Kentepozidis, N., Makrantonakis, P., Xynogalos, S., Christophyllakis, C., Kouroussis, C., Vamvakas, L., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.594 · Cited by 60
Khan, K. A., Wu, F. T. H., Cruz‐Muñoz, W., & Kerbel, R. S. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201708253 · Cited by 56 · cited 1×
“Notably, two other angiocrine mediators, ANG2 and BMP2, have recently gained attention as novel targets because of the consideration of ANG2 inhibitors and Tie2 activators in the ANG/Tie pathway as drug candidates [103] or BMP2 as a target in the calcineurin/NFAT-axis [104].”
BackgroundVascular Mimicry: Concepts and Implications for Anti-Angiogenic Therapy
Dunleavey, J. M., & Dudley, A. C. (2012) · Current Angiogenesis · doi:10.2174/2211552811201020133 · Cited by 56 · cited 1×
“Vascular mimicry may coexist with mosaic vessels where the tumor endothelium is still partially integrated into the vessel wall [110].”
BackgroundHu, H., Zhang, H., Ge, W., Liu, X., Loera, S., Chu, P. G., Chen, H., Peng, J., Zhou, L., Shujing, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0124 · Cited by 52 · cited 1×
“Similarly, in CRC, the TEC-derived matricellular protein SPARCL1 is associated with a positive prognosis in patients and is suspected to mediate the antitumorigenic functions of tumor vessels [99,102].”
Backgroundon behalf of the HORIZON I study group, Cunningham, D., Wong, R. P. W., D’Haens, G., Douillard, J.-Y., Robertson, J. D., Stone, A., & Cutsem, E. V. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.545 · Cited by 49
Bendell, J. C., Saurí, T., Gracián, A. C., Álvarez-Gallego, R., López, C., Alfonso, P. G., Hussein, M., Mirón, M. L. L., Cervantes, A. M. R., Montagut, C. O., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0291 · Cited by 49
ETV2 mediates endothelial transdifferentiation of glioblastoma
Zhao, C., Gomez, G. A., Zhao, Y., Yang, Y., Cao, D., Lu, J. N., Yang, H., & Lin, S. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0007-8 · Cited by 48 · cited 1×
“This was highlighted for GBM patients, in which endothelial cell-like cells were found to transdifferentiate from GBM stem-like cells [112–114].”
BackgroundInfante, J. R., Reid, T. R., Cohn, A. L., Edenfield, W. J., Cescon, T. P., Hamm, J. T., Malik, I. A., Rado, T. A., McGee, P. J., Richards, D., et al. (2013) · Cancer · doi:10.1002/cncr.28112 · Cited by 47
Xu, R., Shen, L., Wang, K.-M., Wu, G., Shi, C., Ding, K., Lin, L.-Z., Wang, J., Xiong, J., Wu, C., et al. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0263-y · Cited by 44
Cutsem, E. V., Prenen, H., D’Haens, G., Bennouna, J., Carrato, A., Ducreux, M. P., Bouché, O., Sobrero, A. F., Latini, L., Staines, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv286 · Cited by 44
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers · doi:10.3390/cancers13051031 · Cited by 43 · cited 4×
“Moreover, the combination of TKIs with chemotherapy in mCRC patients has been disappointing [20].”
BackgroundInfluentialCremolini, C., Marmorino, F., Bergamo, F., Aprile, G., Salvatore, L., Masi, G., Dell’Aquila, E., Antoniotti, C., Murgioni, S., Allegrini, G., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.028 · Cited by 34 · cited 1×
“However, it should be noted that the high frequency of drug administration is challenging for patients, and reports of a lacking advantage of this metronomic therapy schedule also exist [81].”
BackgroundBendell, J. C., Tournigand, C., Świeboda-Sadlej, A., Barone, C. A., Wainberg, Z. A., Kim, J. G., Pericay, C., Pastorelli, D., Tarazi, J., Rosbrook, B., et al. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.09.001 · Cited by 33
García‐Carbonero, R., Cutsem, E. V., Rivera, F., Jassem, J., Gore, I., Tebbutt, N. C., Braiteh, F., Argilés, G., Wainberg, Z. A., Funke, R. P., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0133 · Cited by 33
Schellerer, V. S., Croner, R. S., Weinländer, K., Hohenberger, W., Stürzl, M., & Naschberger, E. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700671 · Cited by 29 · cited 2×
“Moreover, in recent years , it has become clear that ECs in tumors are not just passive conduits of blood that deliver oxygen, nutrients and circulating cells or remove waste products from tissues. is modified from Schellerer et al., Lab Invest 2007 [97].”
BackgroundSelf-citationO’Neil, B. H., Cainap, C. I., Cutsem, E. V., Горбунова, В. А., Karapetis, C. S., Berlin, J. D., Goldberg, R. M., Qin, Q., Qian, J. X., Ricker, J. L., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.04.001 · Cited by 27
Loupakis, F., Hurwitz, H. I., Saltz, L. B., Arnold, D., Grothey, A. F., Nguyen, Q. L., Osborne, S., Talbot, J., Srock, S., & Lenz, H. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0304-6 · Cited by 27 · cited 1×
“This retrospective analysis revealed that bevacizumab had an effect independent of tumor sidedness in mCRC [44].”
BackgroundBenson, A. B., Kišš, I., Bridgewater, J. A., Eskens, F. A. L. M., Sasse, C., Vossen, S., Chen, J., Sant, C. V., Ball, H. A., Keating, A. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3117 · Cited by 26
Sun, Y., Wen, F., Yan, C., Su, L., Luo, J., Chi, W., & Zhang, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727822 · Cited by 26 · cited 1×
“A ROS imbalance in HUVECs after anti-VEGF treatment was also reported by others [119].”
BackgroundEndothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2
Hendrikx, S., Coso, S., Prat-Luri, B., Wetterwald, L., Sabine, A., Franco, C. A., Nassiri, S., Zangger, N., Gerhardt, H., Delorenzi, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.016 · Cited by 22 · cited 1×
“Notably, two other angiocrine mediators, ANG2 and BMP2, have recently gained attention as novel targets because of the consideration of ANG2 inhibitors and Tie2 activators in the ANG/Tie pathway as drug candidates [103] or BMP2 as a target in the calcineurin/NFAT-axis [104].”
BackgroundGrávalos, C., Carrato, A., Tobeña, M., Rodríguez-Garrote, M., Soler, G., Viéitez, J. M., Robles, L., Valladares‐Ayerbes, M., Polo, E., Limón, M. L., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.004 · Cited by 20
Süleyman, H., Kocatürk, H., Bedir, F., Turangezli, O., Arslan, R., Çoban, T. A., & Altuner, D. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/140440 · Cited by 14 · cited 2×
“Anti-VEGF treatment may increase calcium and ROS levels in parallel with decreased ATP production and increased cell damage, as has been observed in renal cells [120].”
BackgroundGarcía‐Carbonero, R., Cutsem, E. V., Rivera, F., Jassem, J., Gore, I., Tebbutt, N. C., Braiteh, F., Argilés, G., Wainberg, Z. A., Funke, R. P., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0133erratum · Cited by 13
Otsu, S., & Hironaka, S. (2023) · Cancers · doi:10.3390/cancers15184564 · Cited by 12 · cited 1×
“It is unclear which of the three antibodies should be preferred in the second-line treatment of mCRC [48].”
BackgroundEttrich, T. J., Perkhofer, L., Decker, T. W., Hofheinz, R., Heinemann, V., Hoffmann, T., Hebart, H. F., Herrmann, T. R. W., Hannig, C. V., Büchner‐Steudel, P., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33296 · Cited by 12
Yang, T. S., Oh, D., Guimbaud, R., Szántó, J., Salek, T., Thurzó, L., Viéitez, J. M., Pover, G. M., & Kim, T. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4084 · Cited by 9
Hashimoto, T., Otsu, S., Hironaka, S., Takashima, A., Mizusawa, J., Kataoka, T., Fukuda, H., Tsukamoto, S., Hamaguchi, T., & Kanemitsu, Y. (2023) · Future Oncology · doi:10.2217/fon-2023-0097 · Cited by 6 · cited 1×
“…et al. initiated the ongoing prospective randomized phase II clinical trial (JCOG2004) to compare bevacizumab with ramucirumab and aflibercept, each in combination with FOLFIRI, in second-line treatment for unresectable CRC after first-line therapy with fluoropyrimidine and oxaliplatin [49].”
Naschberger, E., Fuchs, M., Dickel, N., Kunz, M., Popp, B., Anchang, C. G., Demmler, R., Lyu, Y., Uebe, S., Ekici, A. B., et al. (2023) · 癌症:英文版 · doi:10.1002/cac2.12489 · Cited by 6 · cited 2×
“Compared with their normal colon endothelial counterparts, corresponding PBMCs or tumor cells were found to be genetically stable from TECs isolated from these patients [98].”
BackgroundSelf-citationThomas, H. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.180 · Cited by 1 · cited 1×
“Whether angiocrine antitumorigenic functions of tumor vessels also contribute to the positive effects of vessel normalization strategies warrants further investigation [105].”
Background
Research works printed but not linked: 1
- Folkman J. Antiangiogenesis Agents, in Cancer: Principles and Practice of Oncology Vincent S.H. De Vita T. Jr. Rosenberg S.A. Lippincott Williams & Wilkins Publishers Baltimore, MD, USA 2001
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“However, since anti-angiogenic therapies lead to only modest increases in survival for CRC patients, there is a need for biomarkers for patient stratification, integration of novel combinations of anti-angiogenic drugs with immunotherapy, and better preclinical models of metastatic CRC [211].”
Ma, J., Yuan, H., Zhang, J., Sun, X., Yi, L., Li, W., Li, Z., Fu, C., Zheng, L., Xu, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.001 · Cited by 42
Rahman, M. A., & Ali, M. M. (2024) · Cancers · doi:10.3390/cancers16172975 · Cited by 28
“Antiangiogenic therapies specifically focus on the endothelial cells of recently developed blood vessels with the goal of interrupting the blood flow to the tumor [67].”
BackgroundJordan, A. M., Drake, R. J. G., & Hodivala‐Dilke, K. (2025) · Physiological Reviews · doi:10.1152/physrev.00046.2024 · Cited by 31
Molecular insights into the role of tumor-specific endothelial cells in metastasis
Taher, T. Z., Kheirkhah, A. H., Mehri, S., Mahmoudian, O., Atashi, S., & Kavianpour, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104964 · Cited by 8
Metadata
- Authors
- Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Naschberger, Elisabeth
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-02-22
- Volume
- 16
- Issue
- 5
- Pages
- 890
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10930912
- OpenAlex
- W4392101799
- Cited by
- 11
- References
- 123
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 2
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- German Research Foundation (DFG) FOR 2438, subproject 2 (280163318, 375876048, 437201724, 429280966, 493624887)
- DFG SFB/TRR 241, subproject A06 (280163318, 375876048, 437201724, 429280966, 493624887)
- DFG STU 238/10-1 (280163318, 375876048, 437201724, 429280966, 493624887)
- DFG TRR 305, subproject B08 (280163318, 375876048, 437201724, 429280966, 493624887)
- DFG-NOTICE program (280163318, 375876048, 437201724, 429280966, 493624887)
- W. Lutz Stiftung (280163318, 375876048, 437201724, 429280966, 493624887)
- Forschungsstiftung Medizin am Universitätsklinikum Erlangen (280163318, 375876048, 437201724, 429280966, 493624887)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- colorectal cancer, anti-angiogenic therapy, tumor vasculature, vascular heterogeneity, tumor microenvironment, vascular normalization, treatment resistance, predictive biomarkers, vascular-targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.